Aspirin and the prevention of colorectal cancer: a review of the evidence
- PMID: 8085092
- DOI: 10.1002/ssu.2980100303
Aspirin and the prevention of colorectal cancer: a review of the evidence
Abstract
In all but one of seven recent epidemiologic case-control and cohort studies directly examining the association between aspirin and colorectal cancer and polyps, regular aspirin use reduced the risk of these diseases by about half. Although these studies show a biologically plausible relationship between aspirin and colorectal cancer, information regarding dose and duration and risk change after discontinuation of aspirin is limited and contradictory. Additionally, selection bias, recall bias, and confounding cannot be completed discounted. The one randomized trial of aspirin and placebo showed that aspirin at a dose adequate for preventing myocardial infarction (325 mg every other day) did not reduce colorectal cancer incidence during five years of randomized treatment and follow-up. Further studies need to determine the biologic effects of aspirin, the minimum dose required, and whether other factors, such as age, illnesses, and reasons for aspirin use, modify or confound colorectal cancer development.
Similar articles
-
Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.Important Adv Oncol. 1996:123-37. Important Adv Oncol. 1996. PMID: 8791132 Review.
-
The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.Ann Intern Med. 2007 Mar 6;146(5):365-75. doi: 10.7326/0003-4819-146-5-200703060-00009. Ann Intern Med. 2007. PMID: 17339622 Review.
-
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.Lancet. 2007 May 12;369(9573):1603-13. doi: 10.1016/S0140-6736(07)60747-8. Lancet. 2007. PMID: 17499602 Review.
-
Aspirin and gastrointestinal cancer.Adv Exp Med Biol. 1997;400A:395-402. doi: 10.1007/978-1-4615-5325-0_53. Adv Exp Med Biol. 1997. PMID: 9547582 Review.
-
Aspirin, non-steroidal anti-inflammatory drugs and protection from colorectal cancer: a review of the epidemiological evidence.Scand J Gastroenterol Suppl. 1996;220:137-41. doi: 10.3109/00365529609094766. Scand J Gastroenterol Suppl. 1996. PMID: 8898452 Review.
Cited by
-
Chronic immune activation and inflammation as the cause of malignancy.Br J Cancer. 2001 Aug 17;85(4):473-83. doi: 10.1054/bjoc.2001.1943. Br J Cancer. 2001. PMID: 11506482 Free PMC article. Review.
-
Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.Cancer Immunol Immunother. 2006 Jan;55(1):47-55. doi: 10.1007/s00262-005-0704-3. Epub 2005 Oct 27. Cancer Immunol Immunother. 2006. PMID: 15868166 Free PMC article.
-
The identification of salicylates as normal constituents of serum: a link between diet and health?J Clin Pathol. 1998 Jul;51(7):502-5. doi: 10.1136/jcp.51.7.502. J Clin Pathol. 1998. PMID: 9797725 Free PMC article.
-
Chemopreventive effect of nonsteroidal anti-inflammatory drugs on the development of a new colorectal polyp or adenoma in a high-risk population: a meta-analysis.Curr Ther Res Clin Exp. 2004 Jul;65(4):345-52. doi: 10.1016/j.curtheres.2004.06.001. Curr Ther Res Clin Exp. 2004. PMID: 24672089 Free PMC article.
-
Aspirin and colorectal cancer.Br J Cancer. 1997;76(5):675-7. doi: 10.1038/bjc.1997.444. Br J Cancer. 1997. PMID: 9303370 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical